183 related articles for article (PubMed ID: 37685714)
1. The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus-A Pilot Study.
Király Z; Nagy E; Bokor L; Kovács A; Marschalkó M; Hidvégi B
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685714
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus.
Király Z; Szepesi Á; Sebestyén A; Kuroli E; Rencz F; Tóth B; Bokor L; Szakonyi J; Medvecz M; Hidvégi B
Pathol Oncol Res; 2022; 28():1610521. PubMed ID: 35979531
[TBL] [Abstract][Full Text] [Related]
3. Skin CD4
Zhao Z; Zhu H; Li Q; Liao W; Chen K; Yang M; Long D; He Z; Zhao M; Wu H; Lu Q
J Autoimmun; 2022 Apr; 128():102811. PubMed ID: 35278775
[TBL] [Abstract][Full Text] [Related]
4. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus.
David-Bajar KM; Bennion SD; DeSpain JD; Golitz LE; Lee LA
J Invest Dermatol; 1992 Sep; 99(3):251-7. PubMed ID: 1512459
[TBL] [Abstract][Full Text] [Related]
5. IL-17 in cutaneous lupus erythematosus.
Tanasescu C; Balanescu E; Balanescu P; Olteanu R; Badea C; Grancea C; Vagu C; Bleotu C; Ardeleanu C; Georgescu A
Eur J Intern Med; 2010 Jun; 21(3):202-7. PubMed ID: 20493423
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus.
Méndez-Flores S; Hernández-Molina G; Azamar-Llamas D; Zúñiga J; Romero-Díaz J; Furuzawa-Carballeda J
Cytokine; 2019 Jul; 119():95-112. PubMed ID: 30903869
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus.
Järvinen TM; Hellquist A; Koskenmies S; Einarsdottir E; Koskinen LL; Jeskanen L; Berglind L; Panelius J; Hasan T; Ranki A; Kere J; Saarialho-Kere U
Exp Dermatol; 2010 Feb; 19(2):123-31. PubMed ID: 19758313
[TBL] [Abstract][Full Text] [Related]
8. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
Front Immunol; 2021; 12():775353. PubMed ID: 34868043
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients.
Vera-Recabarren MA; García-Carrasco M; Ramos-Casals M; Herrero C
Br J Dermatol; 2010 Jan; 162(1):91-101. PubMed ID: 19785596
[TBL] [Abstract][Full Text] [Related]
10. Subacute cutaneous lupus erythematosus and discoid lupus erythematosus. Comparative histopathologic findings.
Bangert JL; Freeman RG; Sontheimer RD; Gilliam JN
Arch Dermatol; 1984 Mar; 120(3):332-7. PubMed ID: 6703733
[TBL] [Abstract][Full Text] [Related]
11. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score.
Braunstein I; Klein R; Okawa J; Werth VP
Br J Dermatol; 2012 May; 166(5):971-5. PubMed ID: 22242767
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity.
Hirahara S; Katsumata Y; Kawasumi H; Kawaguchi Y; Harigai M
Lupus; 2020 Jun; 29(7):686-696. PubMed ID: 32264742
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study.
Olbrich H; Kridin K; Zirpel H; Sadik CD; Terheyden P; Thaçi D; Ludwig RJ; Boch K
EBioMedicine; 2023 Jul; 93():104639. PubMed ID: 37285617
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.
Du Y; Nie L; Xu L; Wu X; Zhang S; Xue J
Scand J Immunol; 2020 Jul; 92(1):e12884. PubMed ID: 32243638
[TBL] [Abstract][Full Text] [Related]
15. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus.
Schmitt V; Meuth AM; Amler S; Kuehn E; Haust M; Messer G; Bekou V; Sauerland C; Metze D; Köpcke W; Bonsmann G; Kuhn A
Br J Dermatol; 2010 Jan; 162(1):64-73. PubMed ID: 19712116
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.
Nabatian AS; Bashir MM; Wysocka M; Sharma M; Werth VP
Arthritis Res Ther; 2012 Jan; 14(1):R1. PubMed ID: 22217359
[TBL] [Abstract][Full Text] [Related]
17. Dermoscopic Features of Acute, Subacute, Chronic and Intermittent Subtypes of Cutaneous Lupus Erythematosus in Caucasians.
Żychowska M; Reich A
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887849
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous lupus erythematosus: An update.
Grönhagen CM; Nyberg F
Indian Dermatol Online J; 2014 Jan; 5(1):7-13. PubMed ID: 24616847
[TBL] [Abstract][Full Text] [Related]
19. Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus.
Hu FQ; Zhang YP; Yin J; Tang ZQ; Han YF; Shi ZR; Tan GZ; Wang L
Lupus; 2021 Feb; 30(2):315-319. PubMed ID: 33086919
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune Skin Conditions: Cutaneous Lupus Erythematosus.
Foulke G; Helm LA; Clebak KT; Helm M
FP Essent; 2023 Mar; 526():25-36. PubMed ID: 36913660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
